Vaccine News: Participant In Oxford University And AstraZeneca’s COVID-19 Vaccine Trial In Brazil Dies!
Source: Vaccine News Oct 22, 2020 4 years, 3 weeks, 2 days, 8 hours, 27 minutes ago
Vaccine News: Brazil's health authority Anvisa reported that Brazilian volunteer participating in clinical trials of the COVID-19 vaccine developed by Oxford University and AstraZeneca has died on the 18
th of October.
.jpg)
It was unclear whether the volunteer had received the vaccine or a placebo and in countries like Brazil, the organizers can easily switch the facts in order for cover ups.
Despite the death, the vaccine trial would still continue according to the authorities.
It should be noted that life is considered cheap in South American countries like Brazil, or in countries in Africa and Asia along with corrupted government officials hence pharmaceutical companies from the United States and Europe prefer to conduct their clinical trials in such countries.
To date this is the first officially reported death among the various SARS-CoV-2 coronavirus vaccine trials taking place worldwide.
The organizers of the study however said an independent review had concluded there were no safety concerns and that testing of the vaccine, developed with pharmaceutical firm AstraZeneca, would continue.
According to media sources the volunteer who died was a 28-year-old doctor working on the front lines of the pandemic who died of complications from COVID-19.
The British based Oxford university said in a statement,"All significant medical incidents, whether participants are in the control group or the COVID-19 vaccine group, are independently reviewed. Following careful assessment of this case in Brazil, there have been no concerns about safety of the clinical trial, and the independent review in addition to the Brazilian regulator have recommended that the trial should continue."
Brazil’s national health regulator Anvisa confirmed it had been "formally notified of the case on October 19" and had received a report on the independent review from the security and evaluation committee overseeing the study.
The Brazil’s D'Or Teaching and Research Institute (IDOR), which is helping organize the tests in Brazil, said the independent review process had "raised no doubts about the safety of the study, and recommended it continue."
AstraZeneca and Oxford previously had to suspend testing of the vaccine in September when a volunteer in Britain developed an unexplained illness.
Trials resumed after British regulators and an independent review concluded the illness was not a side effect of the vaccine.
Almost half the volunteers in the final-stage clinical trial ie a double-blind, randomized, controlled study receive a placebo, IDOR said.
Neither the participants nor their families know which vaccine they are being given. This enables the researchers to compare the results for the two groups in order to measure whether the vaccine is effective.
However this dangerous in countries like Brazil where agencies like Anvisa and IDOR are known for corrupted officials that can easily be bought for small sums of money.
To date around 8,000 volunteers have be
en vaccinated so far in Brazil, and more than 20,000 worldwide, it said.
For the study in Brazil, participants must be doctors, nurses or other health sector workers who come into regular contact with the virus.
The Brazilian newspaper Globo said the deceased volunteer was a young doctor who had been treating COVID-19 patients since March in the emergency rooms and intensive care units at two hospitals in Rio de Janeiro.
He graduated from medical school last year, and was in good health prior to contracting the disease, family and friends told the newspaper.
Brazil has plans to purchase the vaccine if it is approved.
The country has had nearly 5.3 million confirmed coronavirus cases - the third highest tally in the world after the US and India and is second only to the US in terms of deaths, with nearly 155,000 registered so far, according to data collated by Johns Hopkins University.
Phase 3 trials in the US remain on hold while the regulator there conducts its own assessment. A senior official was quoted by Bloomberg on Wednesday as saying he expected US trials to restart later in the week.
To date most studies are confirming that effective neutralizing antibodies can only last in the human body for a maximum of about 16 weeks and even then most will have an optimal effectiveness period of between 10 to 12 weeks thus even a successful vaccine that emerges will only provide a short-term protection and serve very little purpose in eradicating the pandemic.
It has also emerging that certain studies on antibodies including one by an ethnic Indian researcher from Arizona are basically being manipulated by certain vaccine developers who are trying to show a longer protection period as there are currently trillions of dollars at stake in these vaccines with many corrupted stakeholders involved including Trump and his cronies and their families.
For more on
Vaccine News, keep on logging to Thailand Medical News.
